PLYMOUTH, Mass.--(BUSINESS WIRE)--Harvest Technologies Corp. (www.harvesttech.com) announced today that a 60-patient clinical trial using the Company’s BMAC™ System to treat patients with non-reconstructible Critical Limb Ischemia (CLI) is now underway at Shri Ramachandra Medical Center, a Harvard Medical international-associated institution based in Chennai, India, one of the largest private healthcare facilities in South Asia. The study is being led by principal investigator Prof. K. S. Vijayaragavan, Head of Vascular Surgery at Sri Ramachandra University. Harvest’s BMAC System is a point-of-care device for concentrating a patient’s own (autologous) bone marrow stem cells in approximately 15 minutes.
